ArticlePloS one2025
Have you heard of Rift Valley fever? Findings from a multi-country study in East and Central Africa.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Seroprevalence of Rift Valley fever virus and factors associated with exposure in south-central Uganda.BMC infectious diseases · 2026Article
- Article
- Rift Valley Fever Outbreak Investigation Associated with a Dairy Farm Abortion Storm, Mbarara District, Western Uganda, 2023.Viruses · 2025Article
Corrections and comments
- Update of
Authors and funding
17 authors.
Funding
Abstract
introductionRift Valley Fever (RVF) has caused several outbreaks across Africa, impacting human health and animal trade. Recent reports indicate sporadic detections of RVF virus among humans and animals in East Africa during inter-epidemic periods. We assessed RVF knowledge levels in East and Central Africa across countries with different epidemiological profiles. MATERIALS AND
methodsIndividuals aged ≥10 years with acute febrile illness were enrolled from six health facilities in Kenya, Uganda, and the Democratic Republic of Congo (DRC). Sociodemographic information was collected, and participants were asked questions regarding their knowledge of RVF transmission, symptoms, prevention, and control. Blood samples were tested for anti-RVF antibodies (IgG and IgM). Knowledge was categorized as absent, basic, or advanced. Descriptive and ordinal logistic regression analysis identified factors associated with RVF knowledge.
resultsAmong 4,806 participants (median age 31, IQR 22-44, 57.5% female), only 20.5% had knowledge of RVF (16.4% basic, 4.1% advanced). Knowledge levels varied by country: DRC (3.1%), Uganda (16.1%), and Kenya (42.6%). RVF seropositivity was 10.4% in Uganda, with much lower rates in Kenya (2.0%) and DRC (1.5%). Factors associated with RVF knowledge included age 21-40 years (aOR 2.03; 95%CI 1,55-2.67) and >40 years (aOR 2.51; 95%CI 1.88-3.37), male gender (aOR 1.44; 95%CI 1.20-1.73), profession as a healthcare worker (aOR 5.63; 95%CI 3.48-9.12), residence in Kenya (aOR 26.8; 95%CI 15.8-48.4) or Uganda (aOR 5.43;95%CI 3.19-9.79), completing primary education (aOR 3.89; 95%CI 2.18-7.52) with advanced (postgraduate) education shown to increase knowledge, (aOR 22.8; 95%CI 4.95-18.6). Other factors included presence of livestock within the homes (aOR 1.26; 95%CI 1.01-1.57) and use of methods to prevent mosquito bites (aOR 1.62; 95%CI 1.32-1.98). Animal farmers, butchers, and those with close animal contact showed no association, despite being at-risk populations.
conclusionOverall RVF knowledge was low across the study sites, with the highest levels observed in Kenya, moderate levels in Uganda despite greater exposure, and markedly low levels in the DRC. Targeted risk communication is urgently needed for high-risk populations in all regions particularly in Uganda, where elevated exposure contrasts with limited knowledge. Increased awareness is crucial for high-exposure groups in all regions, particularly in Uganda where exposure is higher, but knowledge remains relatively low.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.